Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06499181 · ClinicalTrials.gov registry record · Early Phase 1

Multimodal Orthognathic Study Comparing Use of Exparel With Standard of Care.

A Early Phase 1 study, sponsored by United States Naval Medical Center, San Diego.

Completed
Registry status
Early Phase 1
Development phase
86
Enrollment target

NCT06499181 is a Early Phase 1 study that has completed, run by United States Naval Medical Center, San Diego. The registered enrollment target is 86 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06499181, a Early Phase 1 study, has completed, sponsored by United States Naval Medical Center, San Diego.

COMPLETED
Registry status
Early Phase 1
Development phase
86 participants
Enrollment target

Study Summary

A prospective, randomized clinical trial to determine if using liposomal bupivicaine in maxillary orthognathic procedures can reduce the post-operative use of opioids as well as improving the patient's quality of life, versus traditional bupivicaine alone.

Interventions

  • DRUG Bupivacain
  • DRUG Liposomal bupivacaine
  • DRUG Epinephrin

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2018-02-28
Est. Completion 2020-01-01
Phase Early Phase 1

What the Registry Record Tells You About NCT06499181

The ClinicalTrials.gov registry entry for NCT06499181 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United States Naval Medical Center, San Diego, which has 41 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Bupivacain is the first listed.

NCT06499181 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06499181 about?

NCT06499181 is a clinical study titled "Multimodal Orthognathic Study Comparing Use of Exparel With Standard of Care.". A prospective, randomized clinical trial to determine if using liposomal bupivicaine in maxillary orthognathic procedures can reduce the post-operative use of opioids as well as improving the patient's quality of life, versus traditional bupivicaine alone.

What is the current status of trial NCT06499181?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 86 participants. The study started on 2018-02-28. Estimated completion is 2020-01-01.

What interventions are being tested in trial NCT06499181?

The interventions under investigation include: Bupivacain (DRUG), Liposomal bupivacaine (DRUG), Epinephrin (DRUG).

Who is sponsoring clinical trial NCT06499181?

This trial is sponsored by United States Naval Medical Center, San Diego, which has 41 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.